Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis ; volume:23 ; number:1 ; day:3 ; month:5 ; year:2021 ; pages:1-10 ; date:12.2021
Arthritis Research & Therapy ; 23, Heft 1 (3.5.2021), 1-10, 12.2021
- Creator
-
Yamamoto, Yuzuru
Okano, Takaichi
Yamada, Hirotaka
Akashi, Kengo
Sendo, Sho
Ueda, Yo
Morinobu, Akio
Saegusa, Jun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-021-02513-y
- URN
-
urn:nbn:de:101:1-2021090619270991402435
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yamamoto, Yuzuru
- Okano, Takaichi
- Yamada, Hirotaka
- Akashi, Kengo
- Sendo, Sho
- Ueda, Yo
- Morinobu, Akio
- Saegusa, Jun
- SpringerLink (Online service)
Other Objects (12)
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Structural studies of soluble guanylate cyclase
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
Determination of cGMP levels in rodent tissues following oral dosing of a soluble guanylate cyclase stimulator
The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system
Plumbagin attenuates Bleomycin-induced lung fibrosis in mice
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Structural studies of soluble guanylate cyclase
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
Determination of cGMP levels in rodent tissues following oral dosing of a soluble guanylate cyclase stimulator
The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system
Plumbagin attenuates Bleomycin-induced lung fibrosis in mice
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Structural studies of soluble guanylate cyclase
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
Determination of cGMP levels in rodent tissues following oral dosing of a soluble guanylate cyclase stimulator
The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system